GlassScriptPhysician profile
Douglas Mills
NPI 1043519481
$7,636.59
in general payments reported to CMS, 2019-2025
41 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $337 · 2021: $740 · 2022: $1,657 · 2023: $1,799 · 2024: $1,177 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,064 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,064.30 |
| Education | $107.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,107.04 | 2019-2025 | |
| Janssen Biotech, INC. | $594.84 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.32 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $475.47 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $413.14 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $328.58 | 2022-2025 | |
| Celgene Corporation | $314.08 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $266.26 | 2019-2024 | Suflave, Sutab |
| Pfizer INC. | $244.58 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $186.99 | 2019-2025 | Linzess |
| Daiichi Sankyo INC. | $185.06 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $165.95 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $164.92 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $159.40 | 2019-2025 | Stelara, Tremfya, Remicade |
| Ferring Pharmaceuticals INC. | $143.34 | 2022-2023 | Rebyota |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,328.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.